|
Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Appoints Andy Hurley as chief commercial officer, effective from April 10. Hurley joins from Agenus Inc, where he was both chief commercial and medical/clinical officer. He will oversee Shield’s commercial organisation, with responsibility for US sales, marketing, operations, managed markets and patient services. Shield also says it has made progress on US sales force expansion, and now has 33 dedicated sales representatives and five regional sales managers promoting Accrufer, its iron therapy, to Women’s Health and general practitioners in the US. The remaining 17 sales professionals and single regional sales manager are on track to be hired and trained by May 1. Current stock price: 5.81 pence, down 4.8% 12 month change: down 69% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
